{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T18:40:45Z","timestamp":1784832045945,"version":"3.55.0"},"reference-count":70,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:sec>\n            <jats:title>Objectives<\/jats:title>\n            <jats:p>Genetic variation has been a major contributor to interindividual variability of warfarin dosage requirement. The specific genetic factors contributing to warfarin bleeding complications are largely unknown, particularly in Chinese patients. In this study, 896 Chinese patients were enrolled to explore the effect of <jats:italic toggle=\"yes\">CYP2C9<\/jats:italic> and <jats:italic toggle=\"yes\">VKORC1<\/jats:italic> genetic variations on both the efficacy and safety of warfarin therapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods and results<\/jats:title>\n            <jats:p>Univariate analyses unveiled significant associations between two specific single nucleotide polymorphisms rs1057910 in <jats:italic toggle=\"yes\">CYP2C9<\/jats:italic> and rs9923231 in <jats:italic toggle=\"yes\">VKORC1<\/jats:italic> and stable warfarin dosage (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u20050.001). Further, employing multivariate logistic regression analysis adjusted for age, sex and height, the investigation revealed that patients harboring at least one variant allele in <jats:italic toggle=\"yes\">CYP2C9<\/jats:italic> exhibited a heightened risk of bleeding events compared to those with the wild-type genotype (odds ratio\u2005=\u20052.16, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u20050.04). Moreover, a meta-analysis conducted to consolidate findings confirmed the associations of both <jats:italic toggle=\"yes\">CYP2C9<\/jats:italic> (rs1057910) and <jats:italic toggle=\"yes\">VKORC1<\/jats:italic> (rs9923231) with stable warfarin dosage. Notably, <jats:italic toggle=\"yes\">CYP2C9<\/jats:italic> variant genotypes were significantly linked to an increased risk of hemorrhagic complications (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u20050.00001), <jats:italic toggle=\"yes\">VKORC1<\/jats:italic> did not demonstrate a similar association.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>The associations found between specific genetic variants and both stable warfarin dosage and bleeding risk might be the potential significance of gene detection in optimizing warfarin therapy for improving patient efficacy and safety.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/fpc.0000000000000526","type":"journal-article","created":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T12:00:40Z","timestamp":1710244840000},"page":"105-116","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Association between CYP2C9 and VKORC1 genetic polymorphisms and efficacy and safety of warfarin in Chinese patients"],"prefix":"10.1097","volume":"34","author":[{"given":"Suli","family":"Zhang","sequence":"first","affiliation":[{"name":"Bio-X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders (Ministry of Education), Shanghai Jiao Tong University, Shanghai"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingzhe","family":"Zhao","sequence":"additional","affiliation":[{"name":"Affiliated Mental Health Center & Hangzhou Seventh People\u2019s Hospital, Zhejiang University School of Medicine, Hangzhou"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shilong","family":"Zhong","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Guangdong Provincial People\u2019s Hospital, Guangdong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiamin","family":"Niu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Jinan City People\u2019s Hospital, Jinan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Zhou","sequence":"additional","affiliation":[{"name":"Translational Medicine Center, Zhengzhou Central Hospital Affiliated to Zhengzhou University, Zhengzhou"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Zhu","sequence":"additional","affiliation":[{"name":"Shanghai Baio Technology Co., Ltd., Shanghai"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haili","family":"Su","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Huhhot First Hospital, Huhhot"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Cao","sequence":"additional","affiliation":[{"name":"Translational Medicine Center, Zhengzhou Central Hospital Affiliated to Zhengzhou University, Zhengzhou"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinghe","family":"Xing","sequence":"additional","affiliation":[{"name":"Institutes of Biomedical Sciences, Fudan University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongli","family":"Yan","sequence":"additional","affiliation":[{"name":"Reproductive, Medicine Center, Changhai Hospital, Navy Medical University, Shanghai"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Jinan City People\u2019s Hospital, Jinan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qihua","family":"Fu","sequence":"additional","affiliation":[{"name":"Pediatric Translational Medicine Institute, Shanghai Children\u2019s Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai"},{"name":"Shanghai Key Laboratory of Clinical Molecular Diagnostics for Pediatrics, Shanghai"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Geriatrics, Shandong Provincial Third Hospital, Shandong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luan","family":"Chen","sequence":"additional","affiliation":[{"name":"Bio-X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders (Ministry of Education), Shanghai Jiao Tong University, Shanghai"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Yang","sequence":"additional","affiliation":[{"name":"Bio-X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders (Ministry of Education), Shanghai Jiao Tong University, Shanghai"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Zhang","sequence":"additional","affiliation":[{"name":"Bio-X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders (Ministry of Education), Shanghai Jiao Tong University, Shanghai"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Wu","sequence":"additional","affiliation":[{"name":"Bio-X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders (Ministry of Education), Shanghai Jiao Tong University, Shanghai"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"He","sequence":"additional","affiliation":[{"name":"Bio-X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders (Ministry of Education), Shanghai Jiao Tong University, Shanghai"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengying","family":"Qin","sequence":"additional","affiliation":[{"name":"Bio-X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders (Ministry of Education), Shanghai Jiao Tong University, Shanghai"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,3,7]]},"reference":[{"key":"R1-20250808","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/17425255.2020.1711883","article-title":"Genetic influence on bleeding and over-anticoagulation risk in patients undergoing warfarin treatment after heart valve replacements.","volume":"16","author":"Zhou","year":"2020","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"R2-20250808","doi-asserted-by":"crossref","first-page":"587","DOI":"10.2165\/00003088-200140080-00003","article-title":"Pharmacogenetics of warfarin elimination and its clinical implications.","volume":"40","author":"Takahashi","year":"2001","journal-title":"Clin Pharmacokinet"},{"key":"R3-20250808","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1002\/phar.2161","article-title":"Relationship between international normalized ratio and outcomes in modern trials with warfarin controls.","volume":"38","author":"McDowell","year":"2018","journal-title":"Pharmacotherapy"},{"key":"R4-20250808","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ejphar.2013.04.006","article-title":"Influence of CYP2C9 and VKORC1 gene polymorphisms on warfarin dosage over anticoagulation and other adverse outcomes in Indian population.","volume":"710","author":"Gaikwad","year":"2013","journal-title":"Eur J Pharmacol"},{"key":"R5-20250808","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1007\/s12072-018-9922-6","article-title":"Mutations in CYP2C9 and\/or VKORC1 haplotype are associated with higher bleeding complications in patients with Budd\u2013Chiari syndrome on warfarin.","volume":"13","author":"Shukla","year":"2019","journal-title":"Hepatol Int"},{"key":"R6-20250808","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1503\/cmaj.070946","article-title":"Drug interactions with warfarin: what clinicians need to know?","volume":"177","author":"Juurlink","year":"2007","journal-title":"CMAJ"},{"key":"R7-20250808","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1182\/blood-2005-03-1108","article-title":"The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen.","volume":"106","author":"Sconce","year":"2005","journal-title":"Blood"},{"key":"R8-20250808","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1007\/s00228-012-1226-5","article-title":"A new warfarin dosing algorithm including VKORC1 3730 G> A polymorphism: comparison with results obtained by other published algorithms.","volume":"68","author":"Cini","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"key":"R9-20250808","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/jth.13217","article-title":"Structural and functional insights into enzymes of the vitamin K cycle.","volume":"14","author":"Tie","year":"2016","journal-title":"J Thromb Haemost"},{"key":"R10-20250808","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1182\/blood-2004-06-2111","article-title":"A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin.","volume":"105","author":"D\u2019Andrea","year":"2005","journal-title":"Blood"},{"key":"R11-20250808","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1007\/s00228-013-1544-2","article-title":"Cytochrome P450 oxidoreductase genetic polymorphisms A503V and rs2868177 do not significantly affect warfarin stable dosage in Han-Chinese patients with mechanical heart valve replacement.","volume":"69","author":"Tan","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"key":"R12-20250808","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.4314\/tjpr.v17i11.23","article-title":"Effect of CYP2C9 and VKORC1 genetic polymorphisms on warfarin dose requirement in Central China Han populations.","volume":"17","author":"Li","year":"2018","journal-title":"Trop J Phar Res"},{"key":"R13-20250808","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s00228-010-0813-6","article-title":"Increased frequency of CYP2C9 variant alleles and homozygous VKORC1* 2B carriers in warfarin-treated patients with excessive INR response.","volume":"66","author":"Molden","year":"2010","journal-title":"Eur J Clin Pharmacol"},{"key":"R14-20250808","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1056\/NEJMoa0708078","article-title":"Genetic determinants of response to warfarin during initial anticoagulation.","volume":"358","author":"Schwarz","year":"2008","journal-title":"N Engl J Med"},{"key":"R15-20250808","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.clpt.2005.08.006","article-title":"Several-fold increase in risk of overanticoagulation by CYP2C9 mutations.","volume":"78","author":"Lindh","year":"2005","journal-title":"Clin Pharmacol & Ther"},{"key":"R16-20250808","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1182\/blood.V96.5.1816","article-title":"Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment.","volume":"96","author":"Taube","year":"2000","journal-title":"Blood"},{"key":"R17-20250808","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa022913","article-title":"Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.","volume":"349","author":"Hylek","year":"2003","journal-title":"N Engl J Med"},{"key":"R18-20250808","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1001\/jama.287.13.1690","article-title":"Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy.","volume":"287","author":"Higashi","year":"2002","journal-title":"JAMA"},{"key":"R19-20250808","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0140-6736(98)04474-2","article-title":"Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications.","volume":"353","author":"Aithal","year":"1999","journal-title":"Lancet"},{"key":"R20-20250808","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1182\/blood-2008-04-149070","article-title":"The largest prospective warfarin-treated cohort supports genetic forecasting.","volume":"113","author":"Wadelius","year":"2009","journal-title":"Blood"},{"key":"R21-20250808","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1253\/circj.71.761","article-title":"Incidence of major bleeding complication of warfarin therapy in Japanese patients with atrial fibrillation.","volume":"71","author":"Suzuki","year":"2007","journal-title":"Circ J"},{"key":"R22-20250808","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/00008571-200305000-00002","article-title":"Pharmacogenetics of oral anticoagulants.","volume":"13","author":"Daly","year":"2003","journal-title":"Pharmacogenetics"},{"key":"R23-20250808","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/sj.clpt.6100453","article-title":"Prospective study of warfarin dosage requirements based on CYP2C9 and VKORC1 genotypes.","volume":"84","author":"Wen","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"R24-20250808","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/sj.clpt.6100290","article-title":"Influence of CYP2C9 and VKORC1 1173C\/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin.","volume":"83","author":"Limdi","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"R25-20250808","doi-asserted-by":"crossref","first-page":"511","DOI":"10.7326\/0003-4819-118-7-199304010-00005","article-title":"Risk factors for complications of chronic anticoagulation: a multicenter study.","volume":"118","author":"Fihn","year":"1993","journal-title":"Ann Intern Med"},{"key":"R26-20250808","doi-asserted-by":"crossref","first-page":"157","DOI":"10.14715\/cmb\/2021.67.5.22","article-title":"Correlation between CYP2C9 gene polymorphism and warfarin dose in Chinese Han population with coronary heart disease.","volume":"67","author":"Zuo","year":"2021","journal-title":"Cell Mol Biol (Noisy-le-grand)"},{"key":"R27-20250808","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1160\/TH11-12-0848","article-title":"A new algorithm to predict warfarin dose from polymorphisms of CYP4F2 CYP2C9 and VKORC1 and clinical variables: derivation in Han Chinese patients with non valvular atrial fibrillation.","volume":"107","author":"Wei","year":"2012","journal-title":"Thromb Haemost"},{"key":"R28-20250808","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1007\/s00228-017-2265-8","article-title":"The impact of non-genetic and genetic factors on a stable warfarin dose in Thai patients.","volume":"73","author":"Wattanachai","year":"2017","journal-title":"Eur J Clin Pharmacol"},{"key":"R29-20250808","first-page":"18","article-title":"Warfarin dose requirement and cytochrome P450 2C9 and Vitamin K epoxide reductase complex subunit 1-1639 genetic polymorphisms in Thai patients.","volume":"7","author":"Subsuphan","year":"2016","journal-title":"Arch Pharm Pract"},{"key":"R30-20250808","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1007\/s00228-009-0685-9","article-title":"Influence of clinical and genetic factors on warfarin dose requirements among Japanese patients.","volume":"65","author":"Ohno","year":"2009","journal-title":"Eur J Clin Pharmacol"},{"key":"R31-20250808","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.clpt.2006.04.010","article-title":"VKORC1 gene variations are the major contributors of variation in warfarin dose in Japanese patients.","volume":"80","author":"Obayashi","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"R32-20250808","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1080\/00498250801999087","article-title":"Role of pharmacodiagnostic of CYP2C9 variants in the optimization of warfarin therapy in Malaysia: a 6-month follow-up study.","volume":"38","author":"Ngow","year":"2008","journal-title":"Xenobiotica"},{"key":"R33-20250808","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1007\/s00228-007-0381-6","article-title":"Contribution of age body weight and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients.","volume":"63","author":"Miao","year":"2007","journal-title":"Eur J Clin Pharmacol"},{"key":"R34-20250808","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s12185-012-1205-8","article-title":"Influence of warfarin dose-associated genotypes on the risk of hemorrhagic complications in Chinese patients on warfarin.","volume":"96","author":"Ma","year":"2012","journal-title":"Int J Hematol"},{"key":"R35-20250808","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s40262-013-0054-9","article-title":"Prediction of warfarin maintenance dose in Han Chinese patients using a mechanistic model based on genetic and non-genetic factors.","volume":"52","author":"Lu","year":"2013","journal-title":"Clin Pharmacokinet"},{"key":"R36-20250808","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4238\/gmr16038881","article-title":"Pharmacogenetics-based warfarin dose prediction algorithm for patients with heart valve replacement in Southeast China.","volume":"16","author":"Lin","year":"2017","journal-title":"Genet Mol Res"},{"key":"R37-20250808","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s11239-012-0725-7","article-title":"Impact of CYP2C9* 3 VKORC1-1639 CYP4F2 rs2108622 genetic polymorphism and clinical factors on warfarin maintenance dose in Han-Chinese patients.","volume":"34","author":"Liang","year":"2012","journal-title":"J Thromb Thrombolysis"},{"key":"R38-20250808","doi-asserted-by":"crossref","first-page":"453","DOI":"10.3892\/br.2016.617","article-title":"Clinical application of a new warfarin-dosing regimen based on the CYP2C9 and VKORC1 genotypes in atrial fibrillation patients.","volume":"4","author":"Jiang","year":"2016","journal-title":"Biomed Rep"},{"key":"R39-20250808","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1097\/FPC.0b013e328326e0c7","article-title":"Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose: a prospective study in Chinese patients.","volume":"19","author":"Huang","year":"2009","journal-title":"Pharmacogenet Genomics"},{"key":"R40-20250808","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.1365-2125.2010.03698.x","article-title":"CYP4F2 rs2108622: a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement.","volume":"70","author":"Cen","year":"2010","journal-title":"Br J Clin Pharmacol"},{"key":"R41-20250808","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1373\/clinchem.2006.078139","article-title":"Estimation of warfarin maintenance dose based on VKORC1 (\u2212 1639 G> A) and CYP2C9 genotypes.","volume":"53","author":"Zhu","year":"2007","journal-title":"Clin Chem"},{"key":"R42-20250808","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1093\/hmg\/ddi180","article-title":"A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity.","volume":"14","author":"Yuan","year":"2005","journal-title":"Hum Mol Genet"},{"key":"R43-20250808","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1089\/gtmb.2015.0097","article-title":"VKORC1-1639G\/A and 1173 C\/T genetic polymorphisms influence individual differences in warfarin maintenance dose.","volume":"19","author":"Li","year":"2015","journal-title":"Genet Test Mol Biomarkers"},{"key":"R44-20250808","doi-asserted-by":"crossref","first-page":"108","DOI":"10.13181\/mji.v21i2.489","article-title":"The accuracy of warfarin dosage based on VKORC1 and CYP2C9 phenotypes in a Chinese population.","volume":"21","author":"Wijaya","year":"2012","journal-title":"Med J Indones"},{"key":"R45-20250808","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood-2008-03-144899","article-title":"Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement.","volume":"112","author":"Wang","year":"2008","journal-title":"Blood"},{"key":"R46-20250808","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/j.1365-2710.2011.01262.x","article-title":"Clinical relevance of VKORC1 (G-1639A and C1173T) and CYP2C9* 3 among patients on warfarin.","volume":"37","author":"Teh","year":"2012","journal-title":"J Clin Pharm Ther"},{"key":"R47-20250808","doi-asserted-by":"crossref","first-page":"e71505","DOI":"10.1371\/journal.pone.0071505","article-title":"Warfarin anticoagulant therapy: a Southern Italy pharmacogenetics-based dosing model.","volume":"8","author":"Mazzaccara","year":"2013","journal-title":"PLoS One"},{"key":"R48-20250808","doi-asserted-by":"crossref","first-page":"e0116463","DOI":"10.1371\/journal.pone.0116463","article-title":"Warfarin dosage response related pharmacogenetics in Chinese population.","volume":"10","author":"Li","year":"2015","journal-title":"PLoS One"},{"key":"R49-20250808","doi-asserted-by":"crossref","first-page":"475","DOI":"10.2217\/pgs-2022-0014","article-title":"Pharmacogenetic variants influence vitamin K anticoagulant dosing in patients with mechanical prosthetic heart valves.","volume":"23","author":"Koshy","year":"2022","journal-title":"Pharmacogenomics"},{"key":"R50-20250808","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1007\/s11239-016-1436-2","article-title":"Linkage disequilibrium between the CYP2C19* 2* 17 and CYP2C9* 1 alleles and impact of VKORC1 CYP2C9 CYP2C19 gene polymorphisms and gene\u2013gene interactions on warfarin therapy.","volume":"43","author":"Khalighi","year":"2017","journal-title":"J Thromb Thrombolysis"},{"key":"R51-20250808","first-page":"77","article-title":"The Contribution of VKORC1 and CYP2C9 genetic polymorphisms and patients\u2019 demographic characteristics with warfarin maintenance doses: a suggested warfarin dosing algorithm.","volume":"19","author":"Khaleqsefat","year":"2020","journal-title":"Iran J Pharm Res"},{"key":"R52-20250808","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1007\/s00228-010-0863-9","article-title":"VKORC1-1639G> A CYP2C9 EPHX1 691A> G genotype body weight and age are important predictors for warfarin maintenance doses in patients with mechanical heart valve prostheses in southwest China.","volume":"66","author":"Gu","year":"2010","journal-title":"Eur J Clin Pharmacol"},{"key":"R53-20250808","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s00277-010-1119-6","article-title":"Contribution of VKORC1 and CYP2C9 polymorphisms in the interethnic variability of warfarin dose in Malaysian populations.","volume":"90","author":"Gan","year":"2011","journal-title":"Ann Hematol"},{"key":"R54-20250808","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s43440-023-00476-2","article-title":"Evaluation of a warfarin dosing algorithm including CYP2C9 VKORC1 and CYP4F2 polymorphisms and non-genetic determinants for the Iranian population.","volume":"75","author":"Farajzadeh-Dehkordi","year":"2023","journal-title":"Pharmacol Rep"},{"key":"R55-20250808","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s40291-016-0190-7","article-title":"Association of genetic polymorphisms in the VKORC1 and CYP2C9 genes with warfarin dosage in a group of Kuwaiti individuals.","volume":"20","author":"Alrashid","year":"2016","journal-title":"Mol Diagn Ther"},{"key":"R56-20250808","doi-asserted-by":"crossref","first-page":"62","DOI":"10.2174\/1574884711666160118095322","article-title":"Association of genetic polymorphisms of CYP2C9 and VKORC1 with bleeding following warfarin: a case-control study.","volume":"11","author":"Sridharan","year":"2016","journal-title":"Curr Clin Pharmacol"},{"key":"R57-20250808","first-page":"557","article-title":"Association of CYP2C9 gene polymorphism with bleeding as a complication of warfarin therapy.","volume":"32","author":"Topi\u0107","year":"2008","journal-title":"Coll Antropol"},{"key":"R58-20250808","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.taap.2016.08.026","article-title":"Gene polymorphisms and the risk of warfarin-induced bleeding complications at therapeutic international normalized ratio (INR).","volume":"309","author":"Pourgholi","year":"2016","journal-title":"Toxicol Appl Pharmacol"},{"key":"R59-20250808","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s00228-007-0385-2","article-title":"CYP2C9 genotypes and the quality of anticoagulation control with warfarin therapy among Brazilian patients.","volume":"64","author":"Lima","year":"2008","journal-title":"Eur J Clin Pharmacol"},{"key":"R60-20250808","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1007\/s11239-012-0740-8","article-title":"Oral anticoagulation and VKORC1 polymorphism in patients with a mechanical heart prosthesis: a 6-year follow-up.","volume":"34","author":"Giansante","year":"2012","journal-title":"J Thromb Thrombolysis"},{"key":"R61-20250808","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s12288-016-0725-4","article-title":"The influence of CYP2C9 and VKORC1 gene polymorphisms on the response to warfarin in Egyptians.","volume":"34","author":"Bedewy","year":"2018","journal-title":"Indian J Hematol Blood Transfus"},{"key":"R62-20250808","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1002\/jcc.21568","article-title":"Mechanism of the decrease in catalytic activity of human cytochrome P450 2C9 polymorphic variants investigated by computational analysis.","volume":"31","author":"Sano","year":"2010","journal-title":"J Comput Chem"},{"key":"R63-20250808","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/j.1365-2125.2011.04097.x","article-title":"The pharmacogenetics of the response to warfarin in Chinese.","volume":"73","author":"Lam","year":"2012","journal-title":"Br J Clin Pharmacol"},{"key":"R64-20250808","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/jcpt.12143","article-title":"Association of gene polymorphisms with the risk of warfarin bleeding complications at therapeutic INR in patients with mechanical cardiac valves.","volume":"39","author":"An","year":"2014","journal-title":"J Clin Pharm and Ther"},{"key":"R65-20250808","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.1016\/j.ijcard.2013.07.151","article-title":"Influence of CYP2C9 and VKORC1 genotypes on the risk of hemorrhagic complications in warfarin-treated patients: a systematic review and meta-analysis.","volume":"168","author":"Yang","year":"2013","journal-title":"Int J Cardiol"},{"key":"R66-20250808","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s11845-013-0978-y","article-title":"Factors affecting warfarin dose requirements and quality of anticoagulation in adult Egyptian patients: role of gene polymorphism.","volume":"183","author":"Bazan","year":"2014","journal-title":"Ir J Med Sci"},{"key":"R67-20250808","first-page":"399","article-title":"Integrating genomic based information into clinical Warfarin (Coumadin\u00ae) management: an illustrative case report.","volume":"72","author":"LaSala","year":"2008","journal-title":"Conn Med"},{"key":"R68-20250808","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/j.1365-2141.2012.09150.x","article-title":"Polymorphisms in VKORC 1 have more impact than CYP2C9 polymorphisms on early warfarin I nternational N ormalized R atio control and bleeding rates.","volume":"158","author":"Lund","year":"2012","journal-title":"Br J Haematol"},{"key":"R69-20250808","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.bcmd.2009.01.019","article-title":"Influence of CYP2C9 and VKORC1 on warfarin response during initiation of therapy.","volume":"43","author":"Limdi","year":"2009","journal-title":"Blood Cells Mol Dis"},{"key":"R70-20250808","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1160\/TH07-09-0552","article-title":"An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients.","volume":"100","author":"Meckley","year":"2008","journal-title":"Thromb Haemost"}],"container-title":["Pharmacogenetics and Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FPC.0000000000000526","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T14:01:05Z","timestamp":1754661665000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FPC.0000000000000526"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,7]]},"references-count":70,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/fpc.0000000000000526","relation":{},"ISSN":["1744-6872"],"issn-type":[{"value":"1744-6872","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3,7]]}}}